Comparative Pharmacology
Head-to-head clinical analysis: DECADRON LA versus HYDELTRA TBA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DECADRON LA versus HYDELTRA TBA.
DECADRON-LA vs HYDELTRA-TBA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to produce anti-inflammatory and immunosuppressive effects; suppresses migration of polymorphonuclear leukocytes, reverses increased capillary permeability, and reduces cytokine production.
Prednisolone is a synthetic glucocorticoid that binds to the glucocorticoid receptor, modulating gene transcription to suppress inflammation, immune response, and adrenal function.
Dexamethasone acetate (DECADRON-LA) 8-16 mg intramuscularly every 1-3 weeks; adjust based on response and tolerance.
20-40 mg intramuscularly every 3 weeks; for intra-articular use: 20-40 mg per large joint, 10-20 mg per medium joint, 4-10 mg per small joint.
None Documented
None Documented
Terminal elimination half-life is approximately 3-4 hours for dexamethasone, but due to the acetate ester in Decadron-LA, absorption is prolonged, leading to an extended duration of action. The apparent half-life after intramuscular administration is about 3-4 days (72-96 hours) due to slow release from the injection site.
Plasma t1/2 ~2.5-3.5 hours. Duration of adrenal suppression may persist for 24-48 hours.
Renal (<5% unchanged), hepatic metabolism with inactive metabolites excreted renally and fecally; urine and bile are minor routes. Exact % not specified for Decadron-LA (dexamethasone acetate), but dexamethasone is predominantly metabolized and metabolites are excreted renally (~80% of dose) and fecally (~20%).
Primarily renal (80-90% as inactive metabolites and unchanged drug). Biliary excretion accounts for <5%.
Category C
Category C
Corticosteroid
Corticosteroid